Hayley Wyper, BBiomedSc

Pfizer, Inc. Vaccine Research & Development, United Kingdom

Disclosure(s): Pfizer: Stocks/Bonds (Public Company)

Poster(s):

• (P-596) Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT